(STRM) Streamline Health Solutions - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US86323X1063
STRM: Cloud-Based Revenue Software, Coding Analysis Tools, Data Comparison Systems, Clinical Documentation Solutions, Financial Management Services
Streamline Health Solutions Inc (NASDAQ:STRM) is a leading provider of health information technology solutions, catering to hospitals and health systems across North America. The companys product portfolio includes RevID, a cloud-based SaaS solution designed for automated revenue reconciliation, ensuring accurate billing and reducing revenue leakage by identifying discrepancies between clinical and billing departments. Additionally, eValuator offers automated coding analysis, enhancing the efficiency of healthcare providers coding teams. The Data Comparison Engine provides system synchronization and reconciliation, identifying errors between systems. CDI is an integrated software suite that boosts productivity for CDI and Coding staff, facilitating seamless patient data sharing. Financial Management Solutions provide real-time financial data and KPIs to improve revenue realization. The company also offers auditing, coding, and professional services, sold through direct sales and reseller partnerships. Incorporated in 1989 and headquartered in Alpharetta, Georgia, Streamline Health Solutions operates in the Health Care Technology sector.
Looking ahead, the 3-month forecast for Streamline Health Solutions Inc suggests potential price volatility within a range of $2.90 to $3.50, driven by moderate ATR of 0.29. The stocks current price of $3.19 is below its SMA20 ($3.52), SMA50 ($3.72), and SMA200 ($4.75), indicating a bearish trend. However, a low P/S ratio of 0.85 may signal undervaluation, though this is offset by a negative RoE of -0.07, reflecting profitability challenges. Market participants should monitor volume trends, averaging 13,402 over 20 days, for signals of potential trend reversals or continuations.
Additional Sources for STRM Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
STRM Stock Overview
Market Cap in USD | 15m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Technology |
IPO / Inception | 1996-04-18 |
STRM Stock Ratings
Growth 5y | -75.4% |
Fundamental | -26.5% |
Dividend | 0.0% |
Rel. Strength Industry | -58.5 |
Analysts | 5/5 |
Fair Price Momentum | 2.34 USD |
Fair Price DCF | - |
STRM Dividends
No Dividends PaidSTRM Growth Ratios
Growth Correlation 3m | -24.9% |
Growth Correlation 12m | -62.5% |
Growth Correlation 5y | -59.8% |
CAGR 5y | -21.77% |
CAGR/Max DD 5y | -0.23 |
Sharpe Ratio 12m | -0.64 |
Alpha | -68.68 |
Beta | 0.98 |
Volatility | 66.33% |
Current Volume | 2.3k |
Average Volume 20d | 9k |
As of March 16, 2025, the stock is trading at USD 3.07 with a total of 2,265 shares traded.
Over the past week, the price has changed by -3.73%, over one month by -16.35%, over three months by -9.44% and over the past year by -58.15%.
Probably not. Based on ValueRay Fundamental Analyses, Streamline Health Solutions (NASDAQ:STRM) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -26.54 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of STRM as of March 2025 is 2.34. This means that STRM is currently overvalued and has a potential downside of -23.78%.
Streamline Health Solutions has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy STRM.
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, STRM Streamline Health Solutions will be worth about 2.5 in March 2026. The stock is currently trading at 3.07. This means that the stock has a potential downside of -17.59%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 22.5 | 632.9% |
Analysts Target Price | 22.5 | 632.9% |
ValueRay Target Price | 2.5 | -17.6% |